<DOC>
	<DOC>NCT01851746</DOC>
	<brief_summary>The purpose of this study is to evaluate the effectiveness and security of lobaplatin combined with docetaxel in treatment of the sensitive recurrent ovarian cancer.</brief_summary>
	<brief_title>A Study of Docetaxel and Lobaplatin Versus Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (&gt;6 Months) Relapsed Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1. age between 18 and 70 years old 2. singed the information consent form 3. Expected survival time &gt;3 months 4. Recurrence for at least 6 months after receiving initial platinumbased chemotherapy and without cytoreductive surgery indications. 1. Recurrence within 6 months after receiving initial platinumbased chemotherapy 2. without radiographic evidence for tumor recurrence 3. receiving other chemotherapy, hormone therapy, immunotherapy, or radiation therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>recurrent ovarian cancer</keyword>
	<keyword>lobaplatin</keyword>
	<keyword>docetaxel</keyword>
	<keyword>carboplatin</keyword>
</DOC>